IDRX, Inc. clinical trials
Acquired by GlaxoSmithKline, Feb 21, 2025 · source ↗
The registry lists 1 studies whose lead sponsor is IDRX, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 5, 2026.
- 1study on the registry
- 0open to participants now
- 1reach primary completion within a year
Before and after it joined GlaxoSmithKline
- First submitted before IDRX, Inc. became part of GlaxoSmithKline
- 1
- First submitted after IDRX, Inc. became part of GlaxoSmithKline
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs IDRX, Inc.’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- 0 open · 1
Coming up
1 of IDRX, Inc.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- 1MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
The study
Add it to your calendar (.ics) → With an account.
All 1 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Under way, not recruiting1100%
Over the years
- 122
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- IDRX, Inc., a wholly owned subsidiary of GSK, LLC1 study
Something wrong with this grouping? Tell us on the GlaxoSmithKline page.
Studies
Recruiting first, then most recently updated. Showing 1 of 1. All GlaxoSmithKline studies →
- First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsActive, not recruitingNCT05489237Phase 1
Sponsor listed in the registry: IDRX, Inc., a wholly owned subsidiary of GSK, LLC · First submitted before IDRX, Inc. became part of GlaxoSmithKline